Limbic

Key People

• Dr. Ross Harper - CEO & Co-founder
• Sebastiaan de Vries - CTO & Co-founder
• Dr. Max Rollwage - VP of AI & Research
• Scott Osler - VP of Commercial
• Dr. Tobias Hauser - Head of Computational Psychiatry
• Ben Carrington - US General Manager

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with diverse backgrounds in AI, neuroscience, and healthcare.

Dr. Ross Harper, CEO, holds a PhD and has been recognized as Lloyds Bank New Entrepreneur of the Year. CTO Sebastiaan de Vries previously founded Florin, a notable P2P payment app in the Netherlands. The leadership's combined experience in AI, neuroscience, and healthcare provides a solid foundation for the company's initiatives.

Clinical Need

Aspect: Very Strong
Summary: Limbic addresses a critical shortage in mental healthcare services with its AI solutions.

The global mental health sector faces significant challenges, including workforce shortages and increased demand for services. Limbic's AI tools have been utilized by over 260,000 patients within the UK's NHS Talking Therapies, demonstrating their effectiveness in improving access and quality of care.

Competition

Aspect: Somewhat crowded
Summary: The mental health AI market has several players, but Limbic's focus on clinical integration differentiates it.

The mental health AI landscape includes various companies offering digital solutions. However, Limbic's emphasis on integrating AI with existing clinical workflows and its validation within the NHS set it apart from many competitors.

Technical Challenge

Aspect: Moderate
Summary: Developing AI solutions for mental health presents moderate technical challenges, particularly in ensuring accuracy and compliance.

Creating AI tools that accurately assess and support mental health requires sophisticated algorithms and adherence to medical standards. Limbic's achievement of UKCA Class IIa medical device status indicates a commitment to meeting these challenges.

Patent

Aspect: Applied
Summary: Limbic has applied for patents related to its AI technology.

Securing patents can protect Limbic's intellectual property and enhance its market position. Details on the status and scope of these patents would provide further insight into their potential impact.

Financing

Aspect: Well-funded
Summary: Limbic has secured significant funding, including a $14 million round led by Khosla Ventures.

The recent funding round, which included participation from Gaingels and Illusian, provides Limbic with resources to expand its AI solutions to U.S. healthcare providers and further develop its technology.

Regulatory

Aspect: 510k/PMA
Summary: Limbic's AI chatbot has achieved UKCA Class IIa medical device status.

Achieving UKCA Class IIa status indicates that Limbic's AI chatbot meets specific safety and performance standards, facilitating its integration into clinical settings and building trust among healthcare providers.

Opportunity Rollup

Odds of Success

4

Peak Market Share

5.7

Segment CAGR

10.7%

Market Segment

Mental Health AI Technology

Market Sub Segment

Clinical AI Solutions for Mental Healthcare

Key Takeaway

Limbic's AI solutions address a critical need in mental healthcare, supported by a strong team and significant funding, positioning the company for successful expansion into new markets.